We hypothesized that pharmacologic inhibition of EZH1 could potentially overcome the resistance to PI3K inhibition that we observed in AML cells driven by the loss of EZH2 and lead to synthetic lethality in PI3K inhibitor-treated cells. This evidence concerns the gene EZH1 and acute myeloid leukemia.